Elevated C-reactive protein (CRP) levels, an acute-phase protein that reflects systemic inflammation, have been associated with poorer prognosis in melanoma patients treated with ICIs, indicating a potential immunosuppressive environment. This evidence concerns the gene CRP and melanoma.